What Lilly’s $2.75B Bet on AI-Discovered Drug Candidates Means for Drug Development

A collaboration between Insilico Medicine and Eli Lilly marks one of the most structurally significant partnerships to emerge from the intersection of generative AI and pharmaceutical development.1 Under the agreement, Lilly receives an exclusive worldwide license to develop, manufacture, and commercialize a portfolio of novel oral therapeutics currently in preclinical development across multiple indications, candidates that Insilico characterizes as potentially best-in-class. Beyond the licensed portfolio, the two organizations will jointly pursue additional research and development programs, with Lilly selecting the targets and Insilico contributing its Pharma.AI platform infrastructure alongside Lilly's clinical expertise and disease-area knowledge.

The financial structure of the deal offers a rough calibration of how the market is valuing mature artificial intelligence platforms in this space.1 Insilico is eligible to receive an upfront payment of $115 million, with development, regulatory, and commercial milestones that could bring the total value to approximately $2.75 billion, plus tiered royalties on future sales. These figures reflect not just the licensed assets themselves, but the perceived productivity of the underlying platform.

Why Does the Underlying Technology Architecture Matter to Development Teams?

Insilico's approach centers on generative AI applied across the full drug discovery workflow, from target identification through candidate generation.1 Alex Zhavoronkov, founder and chief executive, Insilico, said in a press release,1 "By deploying frontier AI technologies that scale from biomarkers to life models, world models of human and animal life, we can identify multi-purpose targets driving multiple diseases at the same time."

For scientists and project teams navigating complex biology with limited resources, this kind of multi-target identification capability has practical implications, particularly in therapeutic areas where disease mechanisms remain poorly understood or where repurposing potential is underexplored.1

Andrew Adams, group vice president of Molecule Discovery, Lilly, stated in the press release,1 "This collaboration allows us to explore novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas."

The pairing of a platform built for generative molecular design with an organization that has deep clinical development infrastructure raises a question: whether this model, platform company plus established developer, becomes a more common structure for moving AI-generated candidates through the pipeline.1

Zhavoronkov stated, in the press release,1 "Working with Lilly, we aim to deliver transformative therapies that treat diseases with high unmet need. This collaboration is a testament to the power of AI in tackling the most complex challenges in human health."

Whether or not that framing proves out, the deal represents a concrete test case. The preclinical programs now moving under Lilly's development capabilities will, over time, generate real data on how AI-discovered candidates perform as they advance.

What Is Insilico's Track Record with Other Pharma Products?

Insilico reported that newly signed agreements across 2025 totaled $1.3 billion, bringing cumulative collaboration value to $4.6 billion.2 This figure spans drug discovery services, out-licensing arrangements, and co-development structures with more than ten multinational and domestic biopharmaceutical firms.

The commercial growth has run alongside continued platform investment.2 Insilico's software offering now serves 13 of the top 20 global pharmaceutical companies by revenue, with software revenue growing 23.8% year-over-year. Those numbers suggest the underlying technology is being adopted as operational infrastructure, not simply evaluated as a novelty.

On the pipeline side, the organization nominated six new preclinical candidates during 2025 and advanced eight programs in clinical development, including the first clinical proof-of-concept for an AI-discovered drug.2 That milestone carries weight beyond Insilico specifically. It represents the first peer-reviewed, published demonstration that a candidate generated end-to-end by an AI platform can produce meaningful clinical signals.

References

1. Insilico Medicine. Insilico Medicine announces global R&D collaboration with Lilly. Cambridge (MA): Insilico Medicine; 2026 Mar 29 [cited 2026 Mar 31]. Available from: https://insilico.com/news/uiy12zcjg1-insilico-medicine-announces-global-rampd
2. Insilico Medicine. Insilico Medicine announces 2025 annual results, redefining AI-driven drug discovery and development. Cambridge (MA): Insilico Medicine; 2026 Mar 29 [cited 2026 Mar 31]. Available from: https://insilico.com/news/ohz9ozx0t1-insilico-medicine-announces-2025-annual